Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.63 |
| ▸ | MAP3K20 | Q9NYL2 | 11/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | BLK | P51451 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130003 | 0.94 | BRAF (0.66) | BRAFMAP3K20RIPK2ABL1LCK | |
| SCHEMBL14299966 | 0.91 | BRAF (0.75) | BRAFMAP3K20RIPK2ABL1LCK | |
| SCHEMBL10129929 | 0.88 | BRAF (0.63) | BRAFMAP3K20RIPK2 | |
| SCHEMBL10130005 | 0.86 | BRAF (0.73) | BRAFMAP3K20RIPK2ABL1LCK | |
| SCHEMBL10129996 | 0.86 | BRAF (0.84) | BRAFMAP3K20RIPK2ABL1LCK | |
| SCHEMBL14316924 | 0.84 | BRAF (0.64) | BRAFMAP3K20RIPK2ABL1LCK | |
| SCHEMBL10129949 | 0.84 | BRAF (0.64) | BRAFMAP3K20RIPK2ABL1LCK | |
| SCHEMBL10129948 | 0.83 | BRAF (0.62) | BRAFMAP3K20RIPK2ABL1LCK | |
| SCHEMBL10129960 | 0.82 | BRAF (0.67) | BRAFMAP3K20RIPK2ABL1LCK | |
| SCHEMBL10129920 | 0.81 | BRAF (0.59) | BRAFMAP3K20RIPK2ABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655355-B1 | NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-8710055-B2 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012085127-A1 | NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | CDK2, TNNI3K, CDK1 | BRAF 16/4885MAP3K20 22/4885RIPK2 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.